Study identifier:D6970C00011
ClinicalTrials.gov identifier:NCT06336356
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomised, Double-blind, Placebo-controlled Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone Stimulation Test Following Treatment with Baxdrostat for 8 Weeks in Participants with Uncontrolled Hypertension
Uncontrolled Hypertension
Phase 2
No
Baxdrostat, Placebo
All
48
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Arm 1: Baxdrostat 2 mg Participants will receive baxdrostat 2 mg tablet orally once daily. | Drug: Baxdrostat Baxdrostat will be administered orally once daily. Other Name: RO6836191, Other Name: CIN-107 |
Placebo Comparator: Arm 2: Placebo Participants will receive placebo tablet orally once daily. | Drug: Placebo Placebo will be administered orally once daily. |